Completed PHASE1 INTERVENTIONAL 1-arm NCT01845194

Repeated Dose Study for the Investigation of Heritability of and Genetic Influences on Drug Pharmacokinetics

Open Label Repeated Dose Study for the Evaluation of Heritability of and Genetic Influences on Drug Pharmacokinetics (TWINS II)

Sponsor: Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH

Conditions Drug Biotransformation Membrane Transport

Interventions Caffeine Codeine Metoprolol Midazolam Pravastatin Talinolol Torsemide

Updated 6 times since 2017 Last updated: Apr 17, 2014 Started: Dec 31, 2009 Primary completion: Oct 31, 2013 Completion: Oct 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01845194, this PHASE1 trial focuses on Drug Biotransformation and Membrane Transport and remains completed. Sponsored by Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH, it has been updated 6 times since 2009, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Dec 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH

Data source: Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Göttingen, Germany